Form 4: Kewaunee Scientific VP Reports Routine Stock Transactions and RSU Vesting

Ryan S. Noble, VP-Sales & Marketing-Americas at Kewaunee Scientific Corp, reported the vesting of restricted stock units and a subsequent sale of shares for tax withholding purposes.

Summary

• Ryan S. Noble, VP-Sales & Marketing-Americas, acquired 2,959 shares of Common Stock on June 30, 2025, through the vesting of restricted stock units at a price of $0.
• Following this acquisition, Noble's direct beneficial ownership of Common Stock increased to 14,782 shares.
• On July 1, 2025, Noble disposed of 939 shares of Common Stock at a price of $58.34, primarily for tax withholding related to the RSU vesting.
• After the disposition, Noble's direct beneficial ownership of Common Stock stands at 13,843 shares.
• The transactions involved the vesting of Restricted Stock Units from FY23, FY24, and FY25 grants.
• 1,908 FY23 Restricted Stock Units, granted on June 29, 2022, fully vested on June 30, 2025, representing the final installment of service-based units.
• 517 FY24 Restricted Stock Units, granted on June 28, 2023, vested on June 30, 2025, as part of their service-based component.
• 534 FY25 Restricted Stock Units, granted on June 28, 2024, vested on June 30, 2025, as part of their service-based component.

Sentiment

Score: 5

Explanation: The document reports routine insider transactions related to executive compensation, which is neutral in sentiment. It does not indicate any significant positive or negative operational or financial news.

Positives

• The vesting of restricted stock units indicates continued employment of a key executive, Ryan S. Noble, with Kewaunee Scientific Corp.
• The vesting of performance-based restricted stock units (for FY24 and FY25 grants) suggests that certain performance goals may have been met or are on track to be met, although the specific achievement is not detailed in this filing.

Negatives

• A portion of the vested shares (939 shares) was sold to cover tax obligations, which is a common practice but reduces the executive's direct ownership.

Future Outlook

Future vesting of the remaining FY24 and FY25 Restricted Stock Units, particularly the performance-based components, will depend on continued employment and the achievement of specific performance goals over a three-year period.

Industry Context

This Form 4 filing details routine insider stock transactions, which are common occurrences across all industries for publicly traded companies as part of executive compensation and equity incentive plans. It does not provide information on broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The report provides transparency on executive stock ownership and compensation, which is standard for corporate governance. The sale of shares for tax purposes is a minor, routine event and does not indicate a lack of confidence.
• Employees: The vesting of RSUs demonstrates the company's commitment to its executive compensation plans.

Next Steps

• Continued vesting of remaining service-based Restricted Stock Units for FY24 and FY25 grants.
• Potential vesting of performance-based Restricted Stock Units for FY24 and FY25 grants, contingent on achieving defined performance goals over their respective three-year periods.

Key Dates

Keywords

KEQU, Kewaunee Scientific, Form 4, insider transaction, restricted stock units, RSU vesting, stock ownership, Ryan S. Noble, executive compensation